Ravulizumab Outcomes in Polish Patients With aHUS

Recruiting now

Conditions studied: Atypical Hemolytic Uremic Syndrome

In brief

This multicenter, observational cohort study uses retrospective collection of past medical history and prospective follow-up to capture longitudinal data on the management and clinical outcomes of patients with atypical hemolytic uremic syndrome (aHUS) treated with ravulizumab as part of routine clinical practice under Poland's National Drug Program (NDP).

Key facts

Study ID

NCT07399730

Run by

AstraZeneca

People needed

80

Starts

2026-06-24

Expected to finish

2030-12-31

Last updated by the study team

2026-07-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients of all ages diagnosed with atypical hemolytic uremic syndrome (aHUS) who received treatment with ravulizumab under the National Drug Program (NDP) in Poland.
• Patients who are willing to participate in the study and have provided informed consent by signing the informed consent form (ICF).

You may not qualify if…

• Individuals who intend to participate in a clinical trial for atypical hemolytic uremic syndrome (aHUS) on or after the date of their first ravulizumab infusion through the National Drug Program.
• Patients with cognitive impairments, those who are unwilling to participate, or those facing language barriers that hinder adequate comprehension or cooperation.

Where it is running

• Research Site — Katowice, Poland (enrolling)
• Research Site — Warsaw, Poland (enrolling)
• Research Site — Poznan, Poland (enrolling)
• Research Site — Lodz, Poland
• Research Site — Poznan, Poland
• Research Site — Warsaw, Poland
• Research Site — Gdansk, Poland
• Research Site — Wroclaw, Poland
• Research Site — Katowice, Poland
• Research Site — Krakow, Poland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.